Personalized Cancer Vaccine Summit
Evvnt Promotion / evvnt
Archivio
03.12.2024 - 05.12.2024 Hilton Boston Back Bay, 40 Dalton Street, 02115 Boston, Massachusetts, USA
Time: 8:00 AM - 5:00 PM
Temi della conferenza
With recent advancements into Phase II and III trials for personalized cancer vaccines along with 437 other candidates in development, the biopharma industry is at a critical point to demonstrate safe and efficacious results that will offer a real hope for every patient with a cure for cancer.
With recent advancements into Phase II and III trials for personalized cancer vaccines along with 437 other candidates in development, the biopharma industry is at a critical point to demonstrate safe and efficacious results that will offer a real hope for every patient with a cure for cancer.
Professional congress organizer (PCO)
Hanson Wade
Hanson Wade
Annotazioni
URL:
Brochure: https://go.evvnt.com/2558274-3?pid=4832
Speakers: Agnete Fredriksen, Chief Scientific Officer, Nykode Therapeutics, Charles Link, Chief Medical Officer, Syncromune, David Berd, Chief Medical Officer, Biovaxys, and more
URL:
Brochure: https://go.evvnt.com/2558274-3?pid=4832
Speakers: Agnete Fredriksen, Chief Scientific Officer, Nykode Therapeutics, Charles Link, Chief Medical Officer, Syncromune, David Berd, Chief Medical Officer, Biovaxys, and more
Informazioni ed Iscrizioni:
https://go.evvnt.com/2558274-2?pid=4832
Ms. Isabel Weir
Oncologia
Lingua
Inglese
Inglese
Quote del Congresso
USD 2599.00 - USD 5097.00
USD 2599.00 - USD 5097.00
I partecipanti attesi
1000 - 1000
1000 - 1000
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."
